HemoShear Therapeutics Names Robert Gould to Board of Directors

[Charlottesville, VA – July 9, 2015] -- HemoShear Therapeutics, a privately held discovery stage biotechnology company, announced today the appointment of Robert J. Gould, Ph.D., President and CEO of Epizyme, Inc., to the HemoShear Therapeutics Board of Directors.  Dr. Gould brings more than 30 years of experience in the pharmaceutical and biotechnology industry.

 

“Robert is a respected leader with an extensive background in drug discovery and will be invaluable to us as we advance our current proprietary drug discovery programs in rare metabolic disorders and non-alcoholic steatohepatitis (NASH), as well as expand our future pipeline,” said Jim Powers, Chairman and CEO of HemoShear Therapeutics. “The exceptional insights he has gained at Epizyme, the Broad Institute, and Merck will be a critical asset as we apply our deep understanding of human disease biology through our transformational disease models and advanced in silico computational capabilities.”

 

Dr. Gould joined the Board of Epizyme in 2008 and became President and CEO in 2010.  He has guided Epizyme’s growth and development into a clinical stage biopharmaceutical company, developing novel epigenetic therapies for cancer patients. Under his leadership, the company established significant collaborations with Celgene, GSK and Eisai, and completed a successful initial public offering in 2013. Previously, Dr. Gould was Director of Novel Therapeutics at The Broad Institute of MIT and Harvard. Before joining the Broad, Dr. Gould spent 23 years at Merck & Co., Inc., where he held a variety of leadership positions, including Vice President of Licensing and External Research and Vice President of Basic Research at Merck Research Laboratories.  Dr. Gould received a B.A. in chemistry from Spring Arbor College, and a Ph.D. in biochemistry from The University of Iowa and undertook post-doctoral studies at The Johns Hopkins University.

 

“I have been following HemoShear’s progress for several years,” said Dr. Gould.  “They have a unique ability to model and interpret disease biology that allows them to deeply interrogate underlying mechanisms and pathophysiology.  There is a clear recognition in our industry that we need better fundamental models of disease.  I believe their platform has tremendous potential to build a portfolio of novel drug targets and drug candidates leading to important therapies for patients with high unmet need.  I look forward to working with the team to help HemoShear realize their mission to profoundly impact human health.”

 

###

 

About HemoShear Therapeutics

HemoShear Therapeutics is a biotechnology company with a transformational approach to understanding human disease biology driven by REVEAL-Tx™, our revolutionary discovery platform.  REVEAL-Tx™ leads us to proprietary discoveries in metabolic, cardiovascular and inflammatory disorders.  Our current drug discovery efforts are focused on organic acidemias, a group of rare genetic metabolic disorders, and nonalcoholic steatohepatitis (NASH).   

 

At HemoShear Therapeutics, we believe that precision matters; better models of human disease lead to better drug targets and better therapies. We collaborate with leading pharmaceutical and biotechnology companies who share our passion to deeply understand human disease biology and profoundly impact human health.  THINK HUMAN.

 

About REVEAL-Tx ™

REVEAL-Tx™, HemoShear Therapeutics proprietary discovery platform, provides a unique and powerful lens to interrogate biological mechanisms of human disease at a level not possible until now.  In recreating complex pathophysiological pathways, we can identify novel targets, biomarkers and create superior therapeutics.  Our discovery approach is agnostic to therapeutic modality, which allows us to apply the optimal technology to accurately and directly impact the drivers of disease.

 

 

Media Contact:

Lynn Blenkhorn

Feinstein Kean Healthcare

P 617 761 6766

M 508 851 0930

Lynn.blenkhorn@fkhealth.com